Immunicom
Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has held senior positions in global product development in major biotech and MedTech companies and has also co-founded several early-stage life science companies, where he moved products from the laboratory to commercialization. He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 70 research papers, reviews, and patents.
Currently, Dr. Pace is also a Director of Pacira Pharmaceuticals (NASDAQ: PCRX), Simavita Ltd (ASX: SVA), Antisense Therapeutics (ASX: ANP), and Invitrocue (ASX: IVQ), and several private companies. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Ph.D. from MIT, where he was a Fulbright Scholar.
This person is not in the org chart
This person is not in any offices
Immunicom
Immunicom is developing a non-drug-based cancer therapy with the potential to reduce treatment side effects, enhance therapy response rates and improve cancer patients’ quality of life – all at significantly lower costs and without the side effects and complications prevalent in existing immunotherapy approaches. Immunicom's cancer therapy can allow the body’s natural immune system to directly attack cancer while enhancing the effects of other cancer treatments that may be used concurrently.